Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed ...
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback